Antifungal activity of voriconazole

Japanese Journal of Chemotherapy

Volumn 53, Issue SUPPL. 2, 2005, Pages 8-15

  Yamaguchi, Hideyo ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

In vitro antifungal activity; In vivo antifungal activity; New generation azole antifungal agent; Selective action mechanism; Voriconazole

Indexed keywords

ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; FUNGAL STRAIN; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; NONHUMAN; TRICHOSPORON ASAHII;

EID: 29644436193     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Roffey S J, Cole S, Comby P, et al: The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31: 731-741, 2003
2. Sanati H, Belanger P, Fratti B, et al: A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41: 2492-2496, 1997
3. Hitchcock C A, Pye G W, Oliver G P, et al: UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infection: antifungal activity and selectivity in vitro. In Program and Abstracts of the 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995, Abstract F76, p. 125, American Society for Microbiology, Washington, DC, 1995
4. Chávez M, Bernal S, Valverde A, et al: In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44: 697-700, 1999
5. Maesaki S, Iwakawa J, Higashiyama Y, et al: Antifungal activity of a new triazole, voriconazole (UK-109, 496), against clinical isolates of Aspergillus spp. J Infect Chemother 6: 101-103, 2000
6. Pfaller M A, Diekema D J, Jones R N, et al: International surveillance of blood stream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39: 3254-3257, 2001
7. Pfaller M A, Diekema D J, Jones R N, et al: Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with blood stream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40: 852-856, 2002
8. Pelletier R, Loranger L, Marcotte H, et al: Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 51: 479-483, 2002
9. Pfaller M A, Messer S A, Hollis R J, et al: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6, 970 clinical isolates of Candida spp.. Antimicrob Agents Chemother 46: 1723-1727, 2002
10. Serrano M C, Morilla D, Valverde A, et al: Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole. J Clin Microbiol 41: 5270-5272, 2003
11. Takakura S, Fujihara N, Saito T, et al: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53: 283-289, 2004
12. Pfaller M A, Diekema D J, Messer S A, et al: Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antimicrobial Susceptibility Program, 2001. J Clin Microbiol 41: 1440-1446, 2003
13. Pfaller M A, Messer S A, Boyken L, et al: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diag Microbiol Infect Dis 48: 204-205, 2004
14. van Duin D, Cleare W, Zaragoza O, et al: Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 48: 2014-2020, 2004
15. Espinel-Ingroff A, Boyle K, Sheehan D J: In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150: 101-115, 2001
16. Johnson L B, Kauffman C A: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630-637, 2003
17. Japanese source. 36: 61-86, 1995
18. Japanese source. 40: 239-257, 1999
19. Manavathu E K, Cutright J L, Chandrasekar P H: Organism-dependent fungicidal activity of azoles. Antimicrob Agents Chemother 42: 3018-3021, 1998
20. Espinel-Ingroff A: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39: 954-958, 2001
21. Murphy M, Bernard E M, Ishimaru T, et al: Activity of voriconazole (UK-109, 496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 41: 696-698, 1997
22. George D, Miniter P, Andrioli V T: Efficacy of UK-109, 496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40: 86-91, 1996
23. Martin M V, Yates J, Hitchcock C A: Comparison of voriconazole (UK-109, 496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41: 13-16, 1997
24. Chandrasekar P H, Cutright J, Manavathu E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 45: 673-676, 2000
25. Kirkpatrick W R, McAtee R K, Fothergill A W, et al: Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 44: 2865-2868, 2000
26. Ghannoum M A, Okogbule-Wonodi I, Bhat N, et al: Antifungal activity of voriconazole (UK-109, 496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J Chemother 11: 34-39, 1999
27. Hitchcock C A, Andrews R J, Lewis B G H, et al: UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995, Abstract F72, p. 125, American Society for Microbiology, Washington, DC, 1995
28. Troke P F, Brammer K W, Hitchcock C A, et al: UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995, Abstract F73, p.125, American Society for Microbiology, Washington, DC, 1995